Skip to main content

Table 4 Risk Factors for VTE among PsA Patients

From: The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study

   

(Univariate Analysis)

Multivariate analysis

  

PsA+VTE

P value

HR

95% CI

P value

HR

95% CI

Age (Mean± SD, Median)

 

65.2±12.3

<0.0001

1.08

1.06-1.10

<0.0001

1.08

1.05-1.11

sex

Female

39/2807 (1.4%)

0.11

1.53

0.91-2.55

0.34

1.32

0.75-2.30

Male

23/2468 (0.9%)

 

Ref.

    

Socio-economic statusa

1-low

21/1621 (1.3%)

 

Ref.

 

0.32

0.74

0.41-1.34

2-medium

25/2043 (1.2%)

0.75

0.91

0.51-1.63

0.22

0.65

0.33-1.29

3-high

15/1326 (1.1%)

0.61

0.84

0.43-1.63

   

BMIa

BMI<25

13/1480 (0.9%)

 

Ref.

    

BMI≧25<30

20/1795 (1.1%)

0.67

1.16

0.58-2.34

0.46

0.77

0.37-1.57

BMI≧30

28/1765 (.6%)

0.09

1.76

0.91-3.40

0.99

0.99

0.48-2.09

Tobacco use

Yes

25/2227 (1.1%)

0.82

0.94

0.57-1.56

0.90

0.97

0.56-1.66

No

37/3048 (1.2%)

 

Ref.

    

Psoriasis

Yes

52/4244 (1.2%)

0.92

1.04

0.53-2.04

0.23

0.73

0.43-1.22

No

10/1031(0.97%)

 

Ref.

    

Comorbidity

Cancer

       

Yes

8/337 (2.4%)

0.011

2.64

1.25-5.54

0.50

1.30

0.61-2.81

No

54/4939 (1.1%)

 

Ref.

    

Diabetes

 

0.001

     

Yes

29/1781 (1.6%)

 

2.30

1.40-3.82

0.56

1.19

0.65-2.18

No

33/3494 (0.9%)

 

Ref.

    

IHD

       

Yes

14/542 (2.6%)

0.0004

2.93

1.62-5.32

0.81

1.09

0.53-2.25

No

48/4733 (1.0%)

 

Ref.

    

CVA/TIA

 

0.01

     

Yes

6/234 (2.5%)

 

2.99

1.28-6.95

0.69

1.22

0.47-3.15

No

56/5032 (1.1%)

 

Ref.

    

CHF

       

Yes

4/117 (3.4%)

0.001

5.97

2.15-16.60

0.31

1.88

0.55-6.41

No

58/5158 (1.1%)

 

Ref.

    

Hypertension

       

Yes

35/1589 (2.2%)

<0.0001

3.20

1.94-5.29

0.84

1.06

0.59-1.93

No

27/3686 (0.7%)

 

Ref.

    

AF

       

Yes

5/159 (3.1%)

0.003

4.03

1.61-10.1

0.97

0.98

0.33-2.87

No

57/5116 (1.1%)

 

Ref.

    

Vascular disease

       

Yes

5/196 (2.6%)

0.025

2.84

1.14-7.10

0.83

0.90

0.33-2.44

No

57/5079 (1.1%)

 

Ref.

    

COPD

       

Yes

6/465 (1.3%)

0.55

1.30

0.56-3.00

0.77

0.88

0.37-2.08

No

56/4810 (1.2%)

 

Ref.

    

CRF

       

Yes

2/159 (1.3%)

0.45

1.73

0.42-7.01

0.54

0.62

0.14-2.78

No

60/5116 (1.2%)

 

Ref.

    

Past VTE

       

Yes

7/36 (18.0%)

<0.0001

31.63

14.20-70.60

<0.0001

19.60

8.37-45.94

No

55/5236 (1.1%)

 

Ref.

    

Medication

cDMARD

Yes 46/3705 (1.2%)

 

1.56

0.88-2.89

0.25

1.44

0.77-2.67

No 16/1570 (1.0%)

0.12

Ref.

    

bDMARD

Yes 19/1989 (1.0%)

0.39

1.30

0.72-2.37

0.36

1.33

0.73-2.44

No 43/3286 (1.3%)

 

Ref.

    
  1. aPresented data for percentages for socioeconomic status and BMI were calculated from the total number of the available data. Missing data for PsA+VTE group on socioeconomic status was 1/285 (0.35%) and 1/235 (0.43%), respectively.
  2. Abbreviations: AF Atrial fibrillation, c/b DMARD conventional/biologic disease-modifying anti-rheumatic drugs, BMI body mass index, CHF Congestive heart failure, COPD Chronic obstructive pulmonary disease, CRF Chronic renal failure, CVA Cerebrovascular accident, HR Hazard ratio, IHD Ischemic heart disease, PsA Psoriatic arthritis, Ref. Reference for calculation, SD Standard deviation, TIA Transient ischemic attack, VTE Venous thromboembolism.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us